VRX toying with the $158’s surely dismisses the myth that they were bullied by Actavis. The price of the stock always tells the tale, whether people want to hear it or not. Surely, closing a deal to merge Valeant and Allergan would have had an interesting upside, but shareholders are not complaining. Additionally, shareholders of Actavis are not complaining either as the ACT shares toy with new highs as well. SMZ
